Structure’s Oral GLP-1 Hits 16% Placebo-Adjusted Weight Loss at 44 Weeks, Shares Jump 10%

Overview

• ACCESS II Phase 2 reported 16.3% weight loss at 180 mg and 16.0% at 240 mg versus placebo after 44 weeks with no sign of a plateau.
• Favorable tolerability included 2% discontinuations due to adverse events in the open-label extension and 3.4% in the body-composition substudy.
• Results compared favorably with oral competitors, surpassing Novo Nordisk’s oral Wegovy at 13.6% in Phase 3 and Eli Lilly’s orforglipron at about 12.4% in Phase 2 and 11.2% in Phase 3.
• GPCR shares rose roughly 10% to $59.80, valuing the company at about $3.81 billion, though the stock remains down 23% for the year.
• Analyst reactions ranged from H.C. Wainwright lifting its target to $114 and calling the drug highly acquirable to RBC urging caution over placebo behavior and orforglipron’s weaker Phase 3 outcome.